News

Aug 19, 2025

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA

➞

Aug 12, 2025

Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs

➞

Jul 31, 2025

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

➞

Jul 14, 2025

Mabwell Enters into License and Commercialization Agreement with UNILAB to Launch Denosumab Biosimilars in the Philippines

➞

Jul 01, 2025

Mabwell Passes Colombian GMP Inspection with “zero deficiencies” Result for Its Denosumab Injections

➞

Jun 27, 2025

Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection

➞

Jun 26, 2025

Mabwell Bioscience and Calico Life Sciences Announce Exclusive Licensing Agreement for Novel IL-11 Targeting Monoclonal Antibody

➞

Jun 04, 2025

Highlights in Poster Presentations of Mabwell at 2025 ASCO

➞

Jun 04, 2025

Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO

➞

May 29, 2025

Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

➞